Search clinical trials for: olmesartan medoxomil and a diuretic

Total 9405 results

Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Jichi Medical University

Completed

The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)

Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Takeda

Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Safety

Ukraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Hypertension

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Arterial Hypertension
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
Takeda

Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Netherlands, Austria, Germany, Poland, United Kingdom
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Shenzhen People's Hospital

Recruiting

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Essential Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Seoul National University Bundang Hospital

Completed

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (Ang(1-7))

Hypertension | Diabetes Mellitus, Type 2 | Angiotensin/Renin/Aldosterone Hypertension

Korea, Republic of
Schering-Plough

Completed

Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)

Hypertension
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Atherosclerosis

Essential Hypertension | Atherosclerotic Cardiovascular Disease

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.

Bioequivalence

Canada
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of
Daiichi Sankyo, Inc.

Completed

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

Hypertension

United States
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Hypertension and Renal Impairment

Renal Impairment | Essential Hypertension

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Healthy Subjects
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Healthy Subjects
Mylan Pharmaceuticals Inc

Completed

Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States

3

Subscribe